These studies suggest that using TET proteins or CRISPR-Cas9 systems to target the FMR1 promoter and ultimately reverse gene inactivation through epigenome editing could represent a potential therapeutic strategy for FXS. This evidence concerns the gene FMR1 and fragile X syndrome.